目的:代谢综合征(MetS)并发症的发病机制涉及过度产生活性氧,
炎症,和内皮功能障碍。由于番茄红素,高度不稳定的结构和
其对调节代谢系统的显着影响,非常需要一个可以增加其稳定性的公式。
本研究的目的是开发一种包裹番茄红素的方法,并研究其对
炎症标志物的影响,氧化应激,和MetS患者的肝酶。
材料与方法:本研究是一个简单的随机,双盲,基于目标的临床试验,涉及
80名患有MetS的受试者,他们被随机平均分为两组:一组每天服用20毫克
番茄红素,持续8周,安慰剂组遵循与番茄红素组相同的方案,但接受
安慰剂代替番茄红素。它们被称为番茄红素和安慰剂,分别。在4
和8周后的随访中,收集20ml血液用于评估肝酶和一些炎症相关标志物。
结果:在将志愿者分配到各自的小组之前,C反应性
蛋白(CRP)无显著差异,血清肝酶,收缩压和舒张压,或促氧化剂-抗氧化剂平衡(PAB)
在番茄红素和安慰剂组之间。然而,我们随后的分析显示,接受番茄红素治疗组的血清CRP(P=0.001)和PAB(P=0.004)水平
显著降低.我们的包膜番茄红素
治疗与丙氨酸氨基转移酶(ALT)的血清水平无显著差异,天冬氨酸
转移酶(AST),或碱性磷酸酶(ALP)在我们两组之间。
结论:本研究调查了番茄红素对MetS患者的影响。揭示了
对PAB和与MetS相关的炎症的调制作用。然而,
血清ALT水平无显著差异,AST和ALP之间的研讨组(注册号:IRCT20130507013263N3)。
OBJECTIVE: The pathogenesis of metabolic syndrome (MetS) complications involves the excessive production of
reactive oxygen species, inflammation, and endothelial dysfunction. Due to Lycopene, a highly unstable structure and
its significant effects on modulating the metabolic system, there is a strong need for a formula that can increase its
stability. The aim of this study was to develop an approach for encapsulating Lycopene and investigate its effects on
inflammatory markers, oxidative stress, and liver enzymes in patients with MetS.
Materials and Methods: This study is a simple randomized, double-blind, objective-based clinical trial that involved
eighty subjects with MetS, who were equally and randomly assigned to two groups: one group received 20 mg of
Lycopene per day for 8 weeks, and the Placebo group followed the same protocol as the Lycopene group but received
a placebo instead of Lycopene. They were called Lycopene and placebo, respectively. During follow-up visits after 4
and 8 weeks, 20 ml of blood was collected for evaluation of liver enzymes and some inflammatory related markers.
Results: Prior to the assignment of volunteers to their respective groups, there were no notable differences in C-reactive
protein (CRP), serum liver enzymes, systolic and diastolic blood pressure, or pro-oxidant-antioxidant balance (PAB)
between the Lycopene and placebo groups. However, our subsequent analysis revealed a significant reduction in the
serum levels of CRP (P=0.001) and PAB (P=0.004) in the group that received Lycopene. Our encapsulated Lycopene
treatment was not associated with a significant difference in serum levels of alanine aminotransferase (ALT), aspartate
transferase (AST), or alkaline phosphatase (ALP) between our two groups.
Conclusion: This study investigated the impact of Lycopene on individuals with MetS, revealing a noteworthy
modulation effect on PAB and inflammation linked to MetS. However, no significant differences was demonstrated in
serum levels of ALT, AST and ALP between the studied group (registration number: IRCT20130507013263N3).